注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Pliant Therapeutics Inc是一家临床阶段的生物制药公司。该公司专注于发现和开发治疗纤维化及相关疾病的疗法。它专注于通过抑制整合素介导的转化生长因子β (TGF-B)激活治疗纤维化。其主要候选产品PLN-74809是一种口服小分子、双选择性av?6和avB1抑制剂。该公司的第二个候选产品PLN-1474是一种小分子选择性avB1抑制剂,用于治疗与非酒精性脂肪性肝炎相关的肝纤维化。除了其临床项目外,它还在开发其他基于整合素的临床前项目。第一个临床前项目是肿瘤学项目。它的第二个临床前项目是正在开发针对一种未公开整合素受体的变构激动单克隆抗体,用于治疗肌营养不良症,包括杜氏肌营养不良症。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Suzanne L. Bruhn | 58 | 2016 | Independent Director |
Bernard Coulie | 55 | 2016 | President, CEO & Director |
Gayle A. Crowell | 71 | 2019 | Independent Director |
Smital Shah | 46 | 2019 | Independent Director |
Dean Sheppard | - | 2015 | Scientific Founder & Member of Scientific Advisory Board |
Hal Chapman | - | 2015 | Scientific Founder & Member of Scientific Advisory Board |
Rik Derynck | - | 2015 | Scientific Founder & Member of Scientific Advisory Board |
Bill DeGrado | - | 2015 | Scientific Founder & Member of Scientific Advisory Board |
Hoyoung Huh | 54 | 2017 | Independent Chairman |
John T. Curnutte | 73 | 2017 | Independent Director |
Brian W. Metcalf | 78 | - | Member of Scientific Advisory Board |
Bill Greenlee | - | - | Member of Scientific Advisory Board |
Naftali Kaminski | - | - | Member of Scientific Advisory Board |
David R. Phillips | - | - | Member of Scientific Advisory Board |
Paul W. Noble | - | - | Member of Scientific Advisory Board |
Bertus Eksteen | - | - | Member of Scientific Advisory Board |
David E. I. Pyott | 71 | 2021 | Independent Director |
Katharine Knobil | 59 | 2022 | Independent Director |
Thomas A. McCourt | 67 | 2023 | Independent Director |
Darren S. Cline | 60 | 2023 | Independent Director |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核